Agenus Inc. [NASDAQ: AGEN] stock went on an upward path that rose over 0.77% on Tuesday, amounting to a one-week price decrease of less than -9.30%. The company report on August 31, 2020 that Paul Clark Joins Agenus Board of Directors.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Mr. Paul Clark to Agenus’ Board of Directors.
“I am delighted to welcome Paul Clark to our Board at this timely point as we prepare for the commercial launch of our first IO antibodies,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Paul’s broad experience and success in pharmaceutical and biotech companies, which includes the development and the launch of multiple commercial products, as CEO and senior management, will be invaluable to Agenus as we transition into a commercial company with a very deep pipeline.”.
Over the last 12 months, AGEN stock rose by 25.80%. The one-year Agenus Inc. stock forecast points to a potential upside of 39.23. The average equity rating for AGEN stock is currently 1.30, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $741.22 million, with 169.13 million shares outstanding and 152.92 million shares in the current float. Compared to the average trading volume of 2.48M shares, AGEN stock reached a trading volume of 2070302 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $6.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.27, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 7.68.
AGEN Stock Performance Analysis:
Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.30. With this latest performance, AGEN shares gained by 5.33% in over the last four-week period, additionally plugging by 40.57% over the last 6 months – not to mention a rise of 25.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 49.17, with the RSI for the last a single of trading hit 46.07, and the three-weeks RSI is set at 51.75 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 3.76, while it was recorded at 4.07 for the last single week of trading, and 3.39 for the last 200 days.
Insight into Agenus Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 0.70.
AGEN Stock EPS
With the latest financial reports released by the company, Agenus Inc. posted -0.33/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGEN.
Agenus Inc. [AGEN] Insider Position Details
There are presently around $357 million, or 49.50% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: RTW INVESTMENTS, LP with ownership of 12,864,677, which is approximately -1.771% of the company’s market cap and around 9.60% of the total institutional ownership; BLACKROCK INC., holding 12,439,829 shares of the stock with an approximate value of $49.14 million in AGEN stocks shares; and CORMORANT ASSET MANAGEMENT, LP, currently with $43.45 million in AGEN stock with ownership of nearly -9.647% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 79 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 19,748,293 shares. Additionally, 39 investors decreased positions by around 8,517,141 shares, while 31 investors held positions by with 62,223,952 shares. The mentioned changes placed institutional holdings at 90,489,386 shares, according to the latest SEC report filing. AGEN stock had 31 new institutional investments in for a total of 6,309,224 shares, while 13 institutional investors sold positions of 3,475,353 shares during the same period.